idozxun.blogspot.com
“The St. Augustine Amphitheater is stealingt a lot ofour business,” said Ron Barton, executive directodr of the Jacksonville Economic Developmentg Commission during its meeting last “These are events that could easily be booked here as well.” The only plan for the amphitheater at Metro Park is downgrading the slopse of land surrounding the theater to make more room for peopl attending the events there, and it should make them more Barton said. But this is the last stagse of the renovation project for theJacksonville park.
Other renovations include an expandedc children’s playground and discovery area, a new entr y plaza and covered picnic pavilions alon the sides of the greenn atMetro Park. The entire project should costarouns $20 million, and they hope to get it startedx by the first of the Barton said. “A good park like this could be just as effectivew as agood arena,” he said. When formerr mayor John Delaney tried to renovate Metro Park and the amphitheater durinyhis term, the Jacksonville community raised red flaga in fear they would lose some accesws to the park.
In addition, many residentsw across the river were afraisd of the noise the amphitheaterdwould produce, especially on week nights, but they aren’t as concerned now. “The problem last time was that thecity wouldn’ be over the amphitheater anymore, but as long as the city continuesx to run it, that woulde be fine,” said former Jacksonville city council membe Suzanne Jenkins, who chaired the movemen against the amphitheater during Delaney’s administration.
“Theyt do a really good Last time they were worriedthey wouldn’t get a response if they filedf noise complaints to a differenrt company, Jenkins said, but they know the city will She even admitted that they like attendinhg events at the amphitheater in Metrop Park. “I can understand. I’vde been to some things there, and the wholew community across the river is used to itby now,” she “I think this is definitely a dialogue worth
Sunday, January 15, 2012
Friday, January 13, 2012
Genitope, down to a staff of one, forecasts bankruptcy or dissolution - East Bay Business Times:
loxezop.wordpress.com
Fremont-based Genitope remains on the hook — and likelg won’t pay — on real estate, capital and equipment lease obligationstotaling $100 it said in a Securities and Exchangw Commission filing Tuesday. The company, whichn a year ago had more than 200 employees and a sparklintgnew campus, now listsa founder and CEO Dan Denney Jr. as its only employee. The companyu said it still hopes to strikre some sort of deal for its faileeMyVax vaccine, but such overtures have failed to In its SEC filing, Genitope said bankruptcy protection or dissolving the compant would leave remaining shareholders with no financial interest in MyVax or Genitope’sa monoclonal antibody program.
Genitope did not disclose a timeline for bankruptcyor dissolving. The company’s landlord and lenderd will takea hit. Genitope has 12 years remaining on two leaser agreementsfor 220,000 square feet in Ardenwoo d Technology Park, developed by . It has a tota l remaining rental obligationof $97.9 million. It has vacates one of the two buildings and said in the SEC filinf that it plans to leave the second building inthe “very near future.” Genitope’s landlord canceled a three-yearf option to lease additional offics space at Ardenwood after the company missed its May leasw payment.
The company also has a capital lease with and an equipment lease with Genitope still owes $2.7 million on the GE and Cisci leases. “The company is unable to satisfy its obligatione underthese agreements,” Genitope said in the SEC filing. “Thde company does not believe that there is remaining equipmeny securingthe (GE) lease that is availabld for sale to offset its remaining obligatiobn to (GE).” MyVax, the cornerstonse of Genitope’s business plan, takeds a piece of a non-Hodgkin’s lymphomw patient’s tumor and turns that into a only-for-yoju treatment.
While it worked on some it didn’t on others, and the Food and Drug Administratiojn in February rejected a company appeak to lower the bar for a personalizedd treatment by accepting a subset of positive data from the Genitope said in the SEC filing that it continuesa to evaluate datafrom MyVax’s Phase III triao in the hopes of “obtaining value” for But, it added, “the company’s ability to obtain valu e remains highly uncertain.” , hired in Aprio as a financial advisor, contactecd a number of third partiezs about investing in Genitope, a partnership or licensingt or acquiring the MyVax technology.
“To date, no thir party has proposed terms for such a the company said in the SEC The company expected tohave $1 millionj in cash and cash equivalents — net some $630,000o in accounts payable -- plus marketable securitie with an estimated fair market value of about $476,000o as of Aug. 31.
Fremont-based Genitope remains on the hook — and likelg won’t pay — on real estate, capital and equipment lease obligationstotaling $100 it said in a Securities and Exchangw Commission filing Tuesday. The company, whichn a year ago had more than 200 employees and a sparklintgnew campus, now listsa founder and CEO Dan Denney Jr. as its only employee. The companyu said it still hopes to strikre some sort of deal for its faileeMyVax vaccine, but such overtures have failed to In its SEC filing, Genitope said bankruptcy protection or dissolving the compant would leave remaining shareholders with no financial interest in MyVax or Genitope’sa monoclonal antibody program.
Genitope did not disclose a timeline for bankruptcyor dissolving. The company’s landlord and lenderd will takea hit. Genitope has 12 years remaining on two leaser agreementsfor 220,000 square feet in Ardenwoo d Technology Park, developed by . It has a tota l remaining rental obligationof $97.9 million. It has vacates one of the two buildings and said in the SEC filinf that it plans to leave the second building inthe “very near future.” Genitope’s landlord canceled a three-yearf option to lease additional offics space at Ardenwood after the company missed its May leasw payment.
The company also has a capital lease with and an equipment lease with Genitope still owes $2.7 million on the GE and Cisci leases. “The company is unable to satisfy its obligatione underthese agreements,” Genitope said in the SEC filing. “Thde company does not believe that there is remaining equipmeny securingthe (GE) lease that is availabld for sale to offset its remaining obligatiobn to (GE).” MyVax, the cornerstonse of Genitope’s business plan, takeds a piece of a non-Hodgkin’s lymphomw patient’s tumor and turns that into a only-for-yoju treatment.
While it worked on some it didn’t on others, and the Food and Drug Administratiojn in February rejected a company appeak to lower the bar for a personalizedd treatment by accepting a subset of positive data from the Genitope said in the SEC filing that it continuesa to evaluate datafrom MyVax’s Phase III triao in the hopes of “obtaining value” for But, it added, “the company’s ability to obtain valu e remains highly uncertain.” , hired in Aprio as a financial advisor, contactecd a number of third partiezs about investing in Genitope, a partnership or licensingt or acquiring the MyVax technology.
“To date, no thir party has proposed terms for such a the company said in the SEC The company expected tohave $1 millionj in cash and cash equivalents — net some $630,000o in accounts payable -- plus marketable securitie with an estimated fair market value of about $476,000o as of Aug. 31.
Wednesday, January 11, 2012
Stephanie Jordan Big Band to perform 1st day of 2012 New Orleans Jazz Fest - Jazz-Quad
iqukikofor.wordpress.com
Stephanie Jordan Big Band to perform 1st day of 2012 New Orleans Jazz Fest Jazz-Quad The Stephanie Jordan Large Band will perform during the first weekend of Jazz Fest on Friday, April 27, 2012 in the WWOZ Jazz Tent while her brother, trumpeter Marlon Jordan will perform during the second weekend. Stephanie Jordan will fill the WWOZ ... |
Monday, January 9, 2012
Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
gonyzyf.wordpress.com
For latest information on the Companuy andits products, please follow Accesz on and . Access has announced that MuGard(TM) was launched in Germany, Italy, UK, Greece and the Nordicf countries by its Europeancommercial . Under a licens e from Access Pharmaceuticals Inc, SpePharm is responsible for manufacturing, regulatort approval and commercialization in the 27 countriexsof Europe. SpePharm plans to launch MuGarsd in the rest of Europe over the comingg 12 to18 months. The license agreement includes royalties on net salesto Access.
"SpePharm and Accesd are pleased with the commercial launch of MuGardcin Europe, and while it is stillp in the early days, initial feedback has been positive," said , Vice Presidentf of Business Development at "SpePharm is working hard to securd reimbursement from the individual governmental which we believe will greatlyy enhance initial product adoption and ongoing marketing effortws to reach and penetrates the target population of patients requirinvg this important treatment option.," he continued.
MuGard is a ready-to-use mucoadhesive oral woundd rinse for the management of oral a debilitating side effect of many anticancer Upto 40% of all patients receiving chemotheraphy and/or radiotherapy develop moderate to severr mucositis, and almost all patientsz receiving radiotherapy for head and neck cancer and thosew undergoing stem cell transplantation develop Updated clinical practice guidelines for the prevention and treatmentr of mucositis recommend the use of a preventivde oral care regimen as part of routine supportive care alonhg with a therapeutic oral care regimejn if mucositis develops.
The markeg for the treatment of oral mucositis is estimatesd to be in excessof $1 billion MuGard forms a protective coating over the oral mucosz when swirled gently around the In a comparison of cancer patients receiving standardx mucositis care with those patients receivinb MuGard, the incidence and severity of mucositis was significantlhy lower in the MuGard treated group using a validated scale for the assessmentf of oral mucositis. Access Pharmaceuticals, Inc. is an emerging biopharmaceuticall company that develops and commercializews propriety products for the treatmen t and supportive care ofcancer patients.
Access' products include ProLindac(TM), currently in Phase 2 clinica l testing of patients withovarian cancer, and MuGard(TM) for the managemengt of patients with mucositis. The company also has other advanced drug delivert technologiesincluding Cobalamin(TM)-mediated targeted deliverg and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesisw factor and is targeted to breasyt cancer; and Thiarabine, a new generatiojn nucleoside analog which has demonstrated both pre-clinical and clinical activity in certainn cancers.
For additional information on Access Pharmaceuticals, please visirt our website at . This press releaser contains certain statements thatare forward-looking within the meaningb of Section 27a of the Securities Act of 1933, as and that involve risks and These statements include those relating to: clinicap trial plans and timelines and clinical resultsw for ProLindac and product candidates acquired in the MacroChem our ability to execute licensing agreements in the future, Access' planes to continue and initiate clinical trials, the value of its producta in the market (includingb MuGard and the size of the overall market for mucositis its ability to achieve clinical and commercial succesd and its ability to successfully develop marketes products.
These statements are subjectg tonumerous risks, including but not limitee Access' need to obtain additional financinb in order to continue the clinical trial and operationws and to the risks detaileed in Access' Annual Reports on Form 10-K and other reports filec by Access with the Securities and Exchang Commission. SOURCE Access Pharmaceuticals, Inc.
For latest information on the Companuy andits products, please follow Accesz on and . Access has announced that MuGard(TM) was launched in Germany, Italy, UK, Greece and the Nordicf countries by its Europeancommercial . Under a licens e from Access Pharmaceuticals Inc, SpePharm is responsible for manufacturing, regulatort approval and commercialization in the 27 countriexsof Europe. SpePharm plans to launch MuGarsd in the rest of Europe over the comingg 12 to18 months. The license agreement includes royalties on net salesto Access.
"SpePharm and Accesd are pleased with the commercial launch of MuGardcin Europe, and while it is stillp in the early days, initial feedback has been positive," said , Vice Presidentf of Business Development at "SpePharm is working hard to securd reimbursement from the individual governmental which we believe will greatlyy enhance initial product adoption and ongoing marketing effortws to reach and penetrates the target population of patients requirinvg this important treatment option.," he continued.
MuGard is a ready-to-use mucoadhesive oral woundd rinse for the management of oral a debilitating side effect of many anticancer Upto 40% of all patients receiving chemotheraphy and/or radiotherapy develop moderate to severr mucositis, and almost all patientsz receiving radiotherapy for head and neck cancer and thosew undergoing stem cell transplantation develop Updated clinical practice guidelines for the prevention and treatmentr of mucositis recommend the use of a preventivde oral care regimen as part of routine supportive care alonhg with a therapeutic oral care regimejn if mucositis develops.
The markeg for the treatment of oral mucositis is estimatesd to be in excessof $1 billion MuGard forms a protective coating over the oral mucosz when swirled gently around the In a comparison of cancer patients receiving standardx mucositis care with those patients receivinb MuGard, the incidence and severity of mucositis was significantlhy lower in the MuGard treated group using a validated scale for the assessmentf of oral mucositis. Access Pharmaceuticals, Inc. is an emerging biopharmaceuticall company that develops and commercializews propriety products for the treatmen t and supportive care ofcancer patients.
Access' products include ProLindac(TM), currently in Phase 2 clinica l testing of patients withovarian cancer, and MuGard(TM) for the managemengt of patients with mucositis. The company also has other advanced drug delivert technologiesincluding Cobalamin(TM)-mediated targeted deliverg and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesisw factor and is targeted to breasyt cancer; and Thiarabine, a new generatiojn nucleoside analog which has demonstrated both pre-clinical and clinical activity in certainn cancers.
For additional information on Access Pharmaceuticals, please visirt our website at . This press releaser contains certain statements thatare forward-looking within the meaningb of Section 27a of the Securities Act of 1933, as and that involve risks and These statements include those relating to: clinicap trial plans and timelines and clinical resultsw for ProLindac and product candidates acquired in the MacroChem our ability to execute licensing agreements in the future, Access' planes to continue and initiate clinical trials, the value of its producta in the market (includingb MuGard and the size of the overall market for mucositis its ability to achieve clinical and commercial succesd and its ability to successfully develop marketes products.
These statements are subjectg tonumerous risks, including but not limitee Access' need to obtain additional financinb in order to continue the clinical trial and operationws and to the risks detaileed in Access' Annual Reports on Form 10-K and other reports filec by Access with the Securities and Exchang Commission. SOURCE Access Pharmaceuticals, Inc.
Saturday, January 7, 2012
Making Refugees Visible - Duke University
judonebolayb1394.blogspot.com
Duke University | Making Refugees Visible Duke University NY actress Kim Schultz was part of a delegation of American artists who interviewed hundreds of Iraqi refugees on a three-week trip to Jordan, Lebanon, and Syria in 2009. The stories from that trip inspired her one-woman show about Iraqi refugees, ... |
Wednesday, January 4, 2012
Washington Federal seeks stabilizer for portfolio - Puget Sound Business Journal (Seattle):
iwyqaxewun.wordpress.com
After going public in Washington Federal acquired nine thrifts and openef offices in seven other Westerjstates -- Oregon, Utah, Idaho, Nevada, Colorado and Texas. In May, it announced a definitiv agreement to make its10th acquisition. Washington with $7.3 billion in assets, has agrees to pay $65 million for . Unitedf has assets totaling $317 million, four officesa and headquartersin Seattle's International District. When the transaction Washington Federal will appoint United Savings CEO Derem Chinn toits board. "It's an opportunityh for both parties," said Washington Federal CEO Roy adding that the two had talke on and off for a numberof years.
Said "We are very proud to join a compant with a strong reputation for integrity and a lengthy tracko record of outstandingfinancial performance." Whiteheads said Washington Federal has no branches in some of the market s served by United. The fit, moreover, is a good one, he Like Washington Federal, United has kept its operationz simple, and it has similafr deposit andloan products. Whitehead said thingsa at United will change as littleas possible. Customers should noticew scarcely anything other than a new name on the outside Besides acquiringUnited Savings, Washington Federal plans to open othe r branches. It operates a totakl of 115 ineight states.
Puyallup will host the newesf Washington branch. It's building another officew in Bend, Ore., one in Plano, Texas, and two more in Las Washington Federal is a traditional savingsand loan. It takea in deposits and borrows funds and lendsd them mainly to home although it alsomakes multifamily, land and constructiobn loans. It makes fixed-rate, single-family mortgage which now comprise 81 percent of its loan and retains these loanws rather than selling them into thesecondar market.
As a result, today's low interesrt rates present Washington Federal with the challenge of preparing for rising For shouldrates rise, and interest paid to depositoras rise accordingly, Washington Federal would make less or even lose moneyt on its mortgage loans. "This is not the ideal time for fixed-rate loans," Whitehead said. Anticipating that interesty rates will sooner orlate rise, Washington Federal is beefing up its balancd sheet with cash or near-cash, and is building its Whitehead said, "so we can leverage up into a highet interest-rate position.
" Thrifts and bank leverage their capital with deposits and Whitehead said Washington Federal can leverag up with another roughly $3 billion. The idea is that when interes rates rise, Washington Federal can make higher-rate mortgages loans. And the hope is that the interest income producex by these loans will more than offset the higher interestr Washington Federal will have to payfor deposits. Whitehead said, if interest rates don't Washington Federal can buy back stock or increase itsalreadhy "generous" cash dividend.
After going public in Washington Federal acquired nine thrifts and openef offices in seven other Westerjstates -- Oregon, Utah, Idaho, Nevada, Colorado and Texas. In May, it announced a definitiv agreement to make its10th acquisition. Washington with $7.3 billion in assets, has agrees to pay $65 million for . Unitedf has assets totaling $317 million, four officesa and headquartersin Seattle's International District. When the transaction Washington Federal will appoint United Savings CEO Derem Chinn toits board. "It's an opportunityh for both parties," said Washington Federal CEO Roy adding that the two had talke on and off for a numberof years.
Said "We are very proud to join a compant with a strong reputation for integrity and a lengthy tracko record of outstandingfinancial performance." Whiteheads said Washington Federal has no branches in some of the market s served by United. The fit, moreover, is a good one, he Like Washington Federal, United has kept its operationz simple, and it has similafr deposit andloan products. Whitehead said thingsa at United will change as littleas possible. Customers should noticew scarcely anything other than a new name on the outside Besides acquiringUnited Savings, Washington Federal plans to open othe r branches. It operates a totakl of 115 ineight states.
Puyallup will host the newesf Washington branch. It's building another officew in Bend, Ore., one in Plano, Texas, and two more in Las Washington Federal is a traditional savingsand loan. It takea in deposits and borrows funds and lendsd them mainly to home although it alsomakes multifamily, land and constructiobn loans. It makes fixed-rate, single-family mortgage which now comprise 81 percent of its loan and retains these loanws rather than selling them into thesecondar market.
As a result, today's low interesrt rates present Washington Federal with the challenge of preparing for rising For shouldrates rise, and interest paid to depositoras rise accordingly, Washington Federal would make less or even lose moneyt on its mortgage loans. "This is not the ideal time for fixed-rate loans," Whitehead said. Anticipating that interesty rates will sooner orlate rise, Washington Federal is beefing up its balancd sheet with cash or near-cash, and is building its Whitehead said, "so we can leverage up into a highet interest-rate position.
" Thrifts and bank leverage their capital with deposits and Whitehead said Washington Federal can leverag up with another roughly $3 billion. The idea is that when interes rates rise, Washington Federal can make higher-rate mortgages loans. And the hope is that the interest income producex by these loans will more than offset the higher interestr Washington Federal will have to payfor deposits. Whitehead said, if interest rates don't Washington Federal can buy back stock or increase itsalreadhy "generous" cash dividend.
Monday, January 2, 2012
Stem cell startups merge, grab VC cash - San Francisco Business Times:
glafirarynyxu.blogspot.com
IPierian Inc., a South San Franciscop company formed with the merger oftwo venture-backed startups, will focus on manipulatingb mature stem cells into ones with embryonic-likde qualities that can be used to treagt neurodegenerative problems like Lou Gehrig’s The new company is backed by a fresjh round of $10 million from and $1.5 million from . supported by $20 million from and and Pierian Inc. announced the merger on the eve ofthis week’as International Stem Cell meeting in Barcelona. Pierian was foundex by MPM Capital managing directors Ashley Dombkowskik and Robert Millmanand scientists.
IPierian the new company — will be lead by iZumi CEO John Walker, with former executive Corey Goodmahas chairman. IPierian will focus on so-callec induced pluripotent stem cells for patientswith difficult-to-treat neurodegeneratives diseases, like Parkinson’s spinal muscular atrophy and amyotrophic lateralo sclerosis, or Lou Gehrig’s disease. Longer term, the companhy will explore metabolic diseases, cardiovascular diseases and othertherapeutix areas. “Disease-specific pluripotent stem cell s are powerful new tools for drug screening and promis e to revolutionize the treatment ofintractable conditions,” said Dr.
Georgse Daley, who along with fellow Harvarde faculty members Douglas Melton and Lee Rubin were the scientififc foundersof Pierian. IPierian’s scientifivc advisory board will be led by director of stem cell transplantation at the andat , and Dr. Deepakm Srivastava, director of the in San Francisco. Among others on the scientifixc advisory boardare Goodman, who until May headedx in South San Francisco; Dr. Lennart director of the ; Dr. Benoi t Bruneau, an associate investigator at the Gladstone Institutr ofCardiovascular Disease, and Dr. Matthiaws Hebrok, associate director for research at the diabetea center atthe , San Francisco.
Srivastava, Muckre and Bruneau also are professor atUCSF — Mucke in neurology and neurosciences and Bruneau and Srivastava in the pediatrics department. IPierian’s management includes Walker, chief technologu officer Dr. Berta and Dr. Dushyant Pathak, who will lead businesas development. IZumi, formed last year by Kleiner PerkinsCaufielcd & Byers and Highland Capitap Partners, has collaborations with the and the Centerr for iPS Cell Research and Application at Japan’s , wheree Dr. Shinya Yamanaka first succeeded in reprogramming adultg cells in a mouse to becomerlike embryonic-like. Yamanaka also works part time at the Gladstonwe Institutesand UCSF.
Embryonic stem cellz are the gold standard of stem cell research because theyare pluripotent, capable of developing into muscle, skin or other cells. Induced pluripotent cells, like thos created by Yamanaka, are seen by many as a way to sidestel ethical and political issues associated with extracting stem cells from but others say they can causew cancer in mice if any of the genes used to reprogra m the cellsremain active.
IPierian Inc., a South San Franciscop company formed with the merger oftwo venture-backed startups, will focus on manipulatingb mature stem cells into ones with embryonic-likde qualities that can be used to treagt neurodegenerative problems like Lou Gehrig’s The new company is backed by a fresjh round of $10 million from and $1.5 million from . supported by $20 million from and and Pierian Inc. announced the merger on the eve ofthis week’as International Stem Cell meeting in Barcelona. Pierian was foundex by MPM Capital managing directors Ashley Dombkowskik and Robert Millmanand scientists.
IPierian the new company — will be lead by iZumi CEO John Walker, with former executive Corey Goodmahas chairman. IPierian will focus on so-callec induced pluripotent stem cells for patientswith difficult-to-treat neurodegeneratives diseases, like Parkinson’s spinal muscular atrophy and amyotrophic lateralo sclerosis, or Lou Gehrig’s disease. Longer term, the companhy will explore metabolic diseases, cardiovascular diseases and othertherapeutix areas. “Disease-specific pluripotent stem cell s are powerful new tools for drug screening and promis e to revolutionize the treatment ofintractable conditions,” said Dr.
Georgse Daley, who along with fellow Harvarde faculty members Douglas Melton and Lee Rubin were the scientififc foundersof Pierian. IPierian’s scientifivc advisory board will be led by director of stem cell transplantation at the andat , and Dr. Deepakm Srivastava, director of the in San Francisco. Among others on the scientifixc advisory boardare Goodman, who until May headedx in South San Francisco; Dr. Lennart director of the ; Dr. Benoi t Bruneau, an associate investigator at the Gladstone Institutr ofCardiovascular Disease, and Dr. Matthiaws Hebrok, associate director for research at the diabetea center atthe , San Francisco.
Srivastava, Muckre and Bruneau also are professor atUCSF — Mucke in neurology and neurosciences and Bruneau and Srivastava in the pediatrics department. IPierian’s management includes Walker, chief technologu officer Dr. Berta and Dr. Dushyant Pathak, who will lead businesas development. IZumi, formed last year by Kleiner PerkinsCaufielcd & Byers and Highland Capitap Partners, has collaborations with the and the Centerr for iPS Cell Research and Application at Japan’s , wheree Dr. Shinya Yamanaka first succeeded in reprogramming adultg cells in a mouse to becomerlike embryonic-like. Yamanaka also works part time at the Gladstonwe Institutesand UCSF.
Embryonic stem cellz are the gold standard of stem cell research because theyare pluripotent, capable of developing into muscle, skin or other cells. Induced pluripotent cells, like thos created by Yamanaka, are seen by many as a way to sidestel ethical and political issues associated with extracting stem cells from but others say they can causew cancer in mice if any of the genes used to reprogra m the cellsremain active.
Subscribe to:
Posts (Atom)